Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Review, H2 2016

 Table Of Content

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Primary Progressive Multiple Sclerosis (PPMS) Overview 7
Therapeutics Development 8
Pipeline Products for Primary Progressive Multiple Sclerosis (PPMS) - Overview 8
Primary Progressive Multiple Sclerosis (PPMS) - Therapeutics under Development by Companies 9
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Primary Progressive Multiple Sclerosis (PPMS) - Products under Development by Companies 13
Primary Progressive Multiple Sclerosis (PPMS) - Companies Involved in Therapeutics Development 14
F. Hoffmann-La Roche Ltd. 15
Genzyme Corporation 16
Glialogix, Inc. 17
Kyorin Pharmaceutical Co., Ltd. 18
MedDay SA 19
Santhera Pharmaceuticals Holding AG 20
Teva Pharmaceutical Industries Ltd. 21
Primary Progressive Multiple Sclerosis (PPMS) - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
biotin - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
GLX-1112 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
GZ-402668 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
IB-MS - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
ibudilast - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
idebenone - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
laquinimod sodium - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
masitinib - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
ocrelizumab - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Small Molecules for Primary Progressive Multiple Sclerosis and Secondary Progressive Multiple Scleros - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
Stem Cell Therapy for CNS Disorders - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
Primary Progressive Multiple Sclerosis (PPMS) - Dormant Projects 83
Primary Progressive Multiple Sclerosis (PPMS) - Discontinued Products 84
Primary Progressive Multiple Sclerosis (PPMS) - Product Development Milestones 85
Featured News & Press Releases 85
Jul 13, 2016: MediciNova Announces Initiation of Interim Efficacy Analysis in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS 85
Jun 28, 2016: Roche's marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA 86
May 25, 2016: MedDay attends European Academy of Neurology 2016 and presents extension phase results of the MS-SPI trial 87
Apr 21, 2016: MedDay reports full data from pivotal Phase IIb/III MS-SPI / MS-ON studies with MD1003 in Multiple Sclerosis at AAN 87
Mar 22, 2016: FDA Grants Fast Track Designation for MediciNovas MN-166 (ibudilast) for Progressive Multiple Sclerosis 89
Feb 17, 2016: FDA Grants Breakthrough Therapy Designation for Genentech's Investigational Medicine Ocrelizumab in Primary Progressive Multiple Sclerosis 89
Dec 01, 2015: MedDay provides update on MS-ON study of MD-1003 90
Oct 20, 2015: Clinical trial shows first ever positive results in treating primary progressive and relapsing multiple sclerosis 92
Oct 10, 2015: More Results Released from Positive Phase III Clinical Trial of Ocrelizumab in Primary Progressive MS 93
Apr 23, 2015: Teva and Active Biotech Announce First Patient Enrolled in Phase II Study Evaluating Laquinimod for Primary Progressive MS 94
Mar 04, 2015: MedDay to present Pivotal Phase III data in Progressive Multiple Sclerosis at AAN Annual Meeting 94
Feb 01, 2015: MN-166 (ibudilast) Progressive MS Abstract Accepted for Presentation at AAN 67th Annual Meeting in Washington, DC 95
Appendix 96
Methodology 96
Coverage 96
Secondary Research 96
Primary Research 96
Expert Panel Validation 96
Contact Us 96
Disclaimer 97

List Of Tables

Number of Products under Development for Primary Progressive Multiple Sclerosis (PPMS), H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by AB Science SA, H2 2016 14
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 15
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Genzyme Corporation, H2 2016 16
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Glialogix, Inc., H2 2016 17
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 18
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by MedDay SA, H2 2016 19
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Santhera Pharmaceuticals Holding AG, H2 2016 20
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 21
Assessment by Monotherapy Products, H2 2016 22
Number of Products by Stage and Target, H2 2016 24
Number of Products by Stage and Mechanism of Action, H2 2016 26
Number of Products by Stage and Route of Administration, H2 2016 28
Number of Products by Stage and Molecule Type, H2 2016 30
Primary Progressive Multiple Sclerosis (PPMS) - Dormant Projects, H2 2016 83
Primary Progressive Multiple Sclerosis (PPMS) - Discontinued Products, H2 2016 84 

To request a free sample copy of this report, please complete the form below.

Enter captcha code*

We never share your personal data. Privacy policy